Review article · 2023 · Open access
Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist
Neurology, 101(4), 172–180 · Published 6 March 2023 · DOI 10.1212/wnl.0000000000207193
In brief
“Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist” is a 2023 review article by Daniel Andres Alcolea and 4 co-authors, published in Neurology. OpenAlex counts 130 citations as of 18 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 130
- Most cited in
- 2025 (51)
- Field-weighted impact
- 4.37
- References
- 49
- Authors
- 5
Abstract
Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays of blood markers for the detection of amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, and p-tau) and nonspecific blood markers of neuronal (neurofilament light, β-synuclein, and ubiquitin-C-terminal-hydrolase-L1) and glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes in several neurodegenerative diseases. In the near future, these markers may be used for screening, diagnosis, or disease and treatment response monitoring. Blood-based biomarkers for neurodegenerative diseases have been rapidly implemented in research, and they have the potential to enter clinical use soon in different clinical settings. In this review, we will describe the main developments and their potential implications for the general neurologist.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Alcolea, D. A., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023). Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology, 101(4), 172–180. https://doi.org/10.1212/wnl.0000000000207193
MLA 9
Alcolea, Daniel Andres, et al. “Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.” Neurology, vol. 101, no. 4, 2023, pp. 172–180. https://doi.org/10.1212/wnl.0000000000207193.
Chicago
Alcolea, Daniel Andres, Michal Schnaider Beeri, Julio C. Rojas, Raquel C. Gardner, and Alberto Lleó. 2023. “Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.” Neurology 101 (4): 172–180. https://doi.org/10.1212/wnl.0000000000207193.
Harvard
Alcolea, D. A. et al. (2023) ‘Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist’, Neurology, 101(4), pp. 172–180. doi:10.1212/wnl.0000000000207193.
IEEE
D. A. Alcolea, M. S. Beeri, J. C. Rojas, R. C. Gardner, and A. Lleó, “Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist,” Neurology, vol. 101, no. 4, pp. 172–180, 2023, doi: 10.1212/wnl.0000000000207193.
BibTeX
@article{alcolea2023blood,
title = {{Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist}},
author = {Alcolea, Daniel Andres and Beeri, Michal Schnaider and Rojas, Julio C. and Gardner, Raquel C. and Lleó, Alberto},
journal = {Neurology},
year = {2023},
volume = {101},
number = {4},
pages = {172--180},
doi = {10.1212/wnl.0000000000207193},
url = {https://doi.org/10.1212/wnl.0000000000207193}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 8 | |
| 2024 | 29 | |
| 2025 | 51 | |
| 2026 | 42 |
Its field-weighted citation impact is 4.37: it has been cited 4.37 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- blood biomarkers
- neurodegenerative diseases
- Alzheimer's disease
- amyloid-beta
- phosphorylated tau
- neurofilament light chain
- beta-synuclein
- UCHL1
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Alcolea, D. A., Beeri, M. S., Rojas, J. C., Gardner, R. C., & Lleó, A. (2023). Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology, 101(4), 172–180. https://doi.org/10.1212/wnl.0000000000207193
How many times has this paper been cited?
130 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the PDF from this page.
Who wrote this paper?
Daniel Andres Alcolea, Michal Schnaider Beeri, Julio C. Rojas, Raquel C. Gardner, Alberto Lleó.
What is the DOI of this paper?
10.1212/wnl.0000000000207193, permanently at https://doi.org/10.1212/wnl.0000000000207193. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.